Market Outlook
The global hyperpigmentation disorders treatment was anticipated to held a market value of USD 3,915 million in the year 2017 and is expected to grow at a CAGR of 7.1% during the forecast period.
Hyperpigmentation disorder are harmless skin condition caused by darkened skin patches. Rising demand for outpatient dermabrasion procedures, increasing adoption of lasers and growing cosmetics expenditure are expected to drive the growth of the market. Additionally, rising R&D spending followed aggressive strategies by the key market players is generating awareness for the disease boosting the market to grow. According to the American Society of Plastic Surgeons, the number of dermabrasion cosmetic procedures have increased from 42,218 in 2000 to 88,182 in 2016 with a 109% increase during the estimated period.
However, factors such as the lack of adequate reimbursement policy and high costs procedures is estimated to restraint the market.
Get Free Sample Copy at https://www.marketresearchfuture.com/sample_request/7462
Regional Outlook:
The Asia-Pacific are likely to dominate the global hyperpigmentation disorders treatment market. Rising awareness of hyperpigmentation disorders, presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure are some of the factors driving the market. The Americas stood second in the global hyperpigmentation disorders treatment market owing to government funding and support for healthcare sector. Moreover, presence of developed economies like US and Canada provides suitable backgrounds for the market growth. Europe is expected to be the third largest hyperpigmentation disorders treatment market. Following the Europe, the Middle East & Africa is expected to account for the least share of the global hyperpigmentation disorders treatment market.
Competitive Dashboard:
Some of the key players in the global hyperpigmentation disorders treatment market Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.
Brows Complete Premium Research at https://www.marketresearchfuture.com/reports/hyperpigmentation-disorders-treatment-market-7462
Segmentation:
The global hyperpigmentation disorders treatment market has been segmented based on treatment type, disease indication, end-user, and region.
Based on treatment type, the market has been classified as topical drugs, chemical peels, microdermabrasion, laser therapy, phototherapy, and others. The market, by disease indication, has been segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. based on end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The topical drugs segment is expected to hold the largest market share of the hyperpigmentation disorders treatment market, by treatment type, during the forecast period. Also, by disease indication melasma segment register the considerable growth in comparison to other disease indication.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
